AIM ImmunoTech AI Stock Analysis
Want to see AIM full AI Analyst Report?
AIM ImmunoTech (AIM) AI Stock Analysis
AIM ImmunoTech
(NYSE MKT:AIM)
The score is driven primarily by very weak financial performance (minimal revenue, large losses, and persistent cash burn with financing/dilution risk). Technical signals also remain bearish with the stock trading below all key moving averages and negative MACD. Corporate events provide some offset through debt reduction and manufacturing preparation, but equity issuance to achieve these steps limits the positive impact.
AIM ImmunoTech (AIM) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $5.51M
- Dividend Yield
- ―
- Average Volume (3M)
- 4.42M
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 1.05
- Revenue Growth
- -21.49%
- EPS Growth
- 84.62%
- Country
- US
- Employees
- 19
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
AIM ImmunoTech Business Overview & Revenue Model
Company Description
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug of...
AIM ImmunoTech Earnings Call Summary
The earnings call highlighted significant clinical and strategic advancements, including new studies, leadership expansion, and cost reductions. However, financial challenges were noted, with low cash reserves and a risk of delisting from the stock exchange, which the company is actively working to address.
Q4-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the AIM ImmunoTech Fourth Quarter and Full Year 2024 Update Conference Call, CEO Thomas Equels provided extensive guidance on the company's progress and future plans. Key clinical updates included the continuation into Phase 2 of the DURIPANC trial evaluating Ampligen with AstraZeneca's Imfinzi for metastatic pancreatic cancer, and the completion of the AMP-518 study on post-COVID conditions. Financial metrics revealed that research and development expenses decreased to $6.2 million from $10.9 million the previous year, while general and administrative expenses fell to $13.7 million from $21.1 million. The company held approximately $4 million in cash and equivalents as of December 31, 2024. Strategic initiatives to maintain NYSE American listing, including a potential reverse stock split, were also discussed. The call concluded with a commitment to advancing Ampligen's potential across several high-need medical areas.
AIM ImmunoTech Financial Statement Overview
Summary
Very weak fundamentals: extremely small TTM revenue ($95K), deeply negative profitability (negative gross profit; large operating and net losses), and continued cash burn (TTM operating cash flow about -$7.1M; free cash flow about -$7.2M). Low current debt is a partial offset, but the history of negative equity and ongoing losses implies elevated dilution/financing risk.
Income Statement
9Very NegativeBalance Sheet
28NegativeCash Flow
12Very Negative| Breakdown | TTM | Mar 2026 | Dec 2024 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 95.00K | 88.00K | 170.00K | 202.00K | 141.00K | 135.00K |
| Gross Profit | -119.00K | -250.00K | 139.00K | 160.00K | 141.00K | -715.00K |
| EBITDA | -12.46M | -12.94M | -16.49M | -28.72M | -19.19M | -18.29M |
| Net Income | -14.27M | -13.96M | -17.32M | -28.96M | -19.45M | -19.13M |
Balance Sheet | ||||||
| Total Assets | 12.73M | 5.78M | 8.61M | 19.38M | 40.49M | 57.70M |
| Cash, Cash Equivalents and Short-Term Investments | 9.96M | 993.00K | 3.98M | 13.07M | 34.19M | 48.27M |
| Total Debt | 3.92M | 4.90M | 2.94M | 718.00K | 837.00K | 149.00K |
| Total Liabilities | 4.99M | 15.56M | 9.93M | 9.15M | 2.02M | 820.00K |
| Stockholders Equity | 7.74M | -9.78M | -1.32M | 10.23M | 38.47M | 56.88M |
Cash Flow | ||||||
| Free Cash Flow | -7.16M | -11.34M | -14.91M | -21.85M | -16.38M | -14.01M |
| Operating Cash Flow | -7.07M | -10.96M | -14.89M | -21.27M | -16.11M | -13.96M |
| Investing Cash Flow | 52.00K | 1.85M | 4.71M | -832.00K | 10.99M | -631.00K |
| Financing Cash Flow | 17.96M | 10.39M | 6.44M | 485.00K | 80.00K | 8.19M |
AIM ImmunoTech Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIM, the sentiment is Negative. The current price of 0.15 is below the 20-day moving average (MA) of 0.16, below the 50-day MA of 0.19, and below the 200-day MA of 0.45, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 34.42 is Neutral, neither overbought nor oversold. The STOCH value of 47.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AIM.
AIM ImmunoTech Risk Analysis
AIM ImmunoTech disclosed 43 risk factors in its most recent earnings report. AIM ImmunoTech reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskAIM ImmunoTech Peers Comparison
Overall Rating
CVM42Neutral
GTBP42Neutral
HOWL42Neutral
BCAB41Neutral- AIM41Neutral
BOLT40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| CVM | 42Neutral | $24.80M | -0.51 | -202.14% | ― | ― | 73.69% |
| GTBP | 42Neutral | $8.16M | -0.04 | -443.08% | ― | ― | 75.09% |
| HOWL | 42Neutral | $47.14M | -1.35 | -166.98% | ― | ― | 55.37% |
| BCAB | 41Neutral | $3.05M | -0.07 | 89.25% | ― | -22.73% | 53.53% |
| AIM | 41Neutral | $5.51M | -0.04 | 952.76% | ― | -21.49% | 84.62% |
| BOLT | 40Underperform | $12.14M | -0.39 | -126.23% | ― | 12.79% | 37.93% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AIM | Aim Immunotech Inc. | 0.15 | -1.32 | -89.88% | |
| CVM | Cel-sci | 1.31 | -5.32 | -80.24% | |
| GTBP | Gt Biopharma, Inc. | 3.95 | -14.29 | -78.35% | |
| BCAB | Bioatla, Inc. | 1.85 | -31.13 | -94.39% | |
| BOLT | Bolt Biotherapeutics, Inc. | 6.26 | 1.56 | 33.19% | |
| HOWL | Werewolf Therapeutics, Inc. | 0.99 | 0.06 | 6.58% |
AIM ImmunoTech Corporate Events
AIM ImmunoTech Furnishes Corporate Presentation on Ampligen Opportunity
NeutralOn November 5, 2026, AIM ImmunoTech furnished a corporate presentation titled “The Ampligen Opportunity” alongside a company-issued press release. The supplied release text contained no underlying presentation content beyond image placeholders, so it...
AIM ImmunoTech Executes Debt-Reducing Equity Exchange Agreements
PositiveFrom Sept. 8 to Sept. 9, 2026, AIM ImmunoTech entered into two exchange agreements and related partitioned promissory notes with Streeterville Capital LLC, converting about $400,000 of a November 18, 2025 promissory note into 1,749,434 shares of comm...
AIM ImmunoTech Reduces Debt via Equity Exchange Agreements
NeutralOn September 3 and 4, 2026, AIM ImmunoTech entered into two exchange agreements with Streeterville Capital that partitioned a previously issued November 18, 2025 promissory note and converted about $450,000 of the debt into 1,921,441 shares of common...
AIM ImmunoTech Extinguishes Debt Through Equity Exchanges
PositiveBetween August 31 and September 3, 2026, AIM ImmunoTech entered into five exchange agreements and related partitioned promissory notes with Streeterville Capital, converting approximately $1.22 million of a February 16, 2024 promissory note into 5,06...
AIM ImmunoTech CEO Urges Biodefense Military Integration
PositiveOn August 11, 2026, AIM ImmunoTech’s CEO Thomas K. Equels authored a sponsored article in online defense outlet Breaking Defense arguing that biodefense should be treated as core military force protection, not just a public health function. He highli...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026